Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3043 in Advanced Solid Tumors
NCT07902804Phase 1Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI3043 in solid tumor, sponsored by Innovent Biologics. Primary endpoints: Adverse Events up to 2 years, Objective Response Rate up to 2 years and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
IBI3043
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07902804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902804.